Regenerative collagen biomembrane: Interim results of a Phase I veterinary clinical trial for skin repair.

Autor:	Kaasi A; Eva Scientific Ltd, São Paulo, 047040-030, Brazil.; National Institute of Biofabrication, Campinas, 13083-852, Brazil.; University of Campinas, Cidade Universitária , Campinas, 13083-970, Brazil., Lima-Neto JF; Sorocaba Veterinary Hospital, Sorocaba, 18046-700, Brazil., Matiello-Filho JA; Sorocaba Veterinary Hospital, Sorocaba, 18046-700, Brazil., Calejo MHS; Sorocaba Veterinary Hospital, Sorocaba, 18046-700, Brazil., Jardini AL; National Institute of Biofabrication, Campinas, 13083-852, Brazil.; University of Campinas, Cidade Universitária , Campinas, 13083-970, Brazil., Kharmandayan P; National Institute of Biofabrication, Campinas, 13083-852, Brazil.; University of Campinas, Cidade Universitária , Campinas, 13083-970, Brazil.
Jazyk:	angličtina
Zdroj:	F1000Research [F1000Res] 2018 Jun 12; Vol. 7, pp. 729. Date of Electronic Publication: 2018 Jun 12 (Print Publication: 2018).
DOI:	10.12688/f1000research.15138.1
Abstrakt:	Background: The availability of commercial tissue engineering skin repair products for veterinary use is scarce or non-existent. To assess features of novel veterinary tissue engineered medical devices, it is therefore reasonable to compare with currently available human devices. During the development and regulatory approval phases, human medical devices that may have been identified as comparable to a novel veterinary device, may serve as predicate devices and accelerate approval in the veterinary domain. The purpose of the study was to evaluate safety and efficacy of the biomembrane for use in skin repair indications. Methods: In the study as a whole (3 year total length), 15 patients (animals), dogs and cats (male/female, <8 years) with skin lesions of different etiologies considered difficult to heal (size, >2 cm), with a wound depth equivalent to 2nd/3rd degree burns are to be studied from Day 0 to Day 120-240, post-application of the biomembrane. This interim report covers the 5 patients assessed to date and deemed eligible, of which 3 enrolled, and 2 have completed the treatment. Wound beds were prepared and acellular collagen biomembranes (Eva Scientific Ltd, São Paulo, Brazil) applied directly onto the wounds, and sutured at the margins to the patient's adjacent tissue. Wound size over time, healing rate, general skin quality and suppleness were assessed as outcomes. Qualitative (appearance and palpation) and quantitative (based on Image Analysis of photographs) wound assessment techniques were used. Results: Both patients' wounds healed fully, with no adverse effects, and the healing rate was comparable in both, maxing out at approximately 1 cm 2 /day. Conclusions: Early results on the biomembrane's safety and efficacy indicate suitability for skin repair usage in veterinary patients. Competing Interests: Competing interests: The first author (A.K.) is the founder and shareholder of Eva Scientific Ltd, where the biomembrane used in this clinical trial was developed and is sold. The co-authors are veterinary practitioners of Sorocaba Veterinary Hospital (J.F.L.N., J.A.M.F. and M.H.S.C.) and full-time employees of University of Campinas (A.L.J. and P.K.). All co-authors read and agreed to the manuscript and had full access to the data, and attest to the study's impartiality as a whole, as well as declare no competing interests.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu